



(51) International Patent Classification:

A61K 31/47 (2006.01) A61K 31/452 (2006.01)
A61K 31/435 (2006.01) A61K 31/33 (2006.01)
A61K 31/4709 (2006.01)

(21) International Application Number:

PCT/US2023/010493

(22) International Filing Date:

10 January 2023 (10.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/298,551 11 January 2022 (11.01.2022) US

(71) Applicant: **CRINETICS PHARMACEUTICALS, Inc.**
[US/US]; 10222 Barnes Canyon Road, Building #2, San
Diego, California 92121 (US).

(72) Inventors: **LAGAST, Hjalmar**; 10222 Barnes Canyon
Road, Building #2, San Diego, California 92121 (US).
KRASNER, Alan S.; 10222 Barnes Canyon Road, Build-
ing #2, San Diego, California 92121 (US). **USISKIN, Keith S.**;
10222 Barnes Canyon Road, Building #2, San Diego,
California 92121 (US).

(74) Agent: **ZUNIC, Valentin B.**; WILSON SONSINI, 650
Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF CARCINOID SYNDROME

Fig. 3



(57) Abstract: Described herein are uses of the somatostatin modulator 3-[4-(4-amino-piperidin-1-yl)-3-(3,5-difluoro-phenyl)-quino-
lin-6-yl]-2-hydroxy-benzonitrile, or a pharmaceutically acceptable salt thereof, in the treatment of carcinoid syndrome.